BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 28667082)

  • 21. Semiquantitative 123I-Metaiodobenzylguanidine Scintigraphy to Distinguish Pheochromocytoma and Paraganglioma from Physiologic Adrenal Uptake and Its Correlation with Genotype-Dependent Expression of Catecholamine Transporters.
    van Berkel A; Rao JU; Lenders JW; Pellegata NS; Kusters B; Piscaer I; Hermus AR; Plantinga TS; Langenhuijsen JF; Vriens D; Janssen MJ; Gotthardt M; Timmers HJ
    J Nucl Med; 2015 Jun; 56(6):839-46. PubMed ID: 25883126
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular imaging and radionuclide therapy of pheochromocytoma and paraganglioma in the era of genomic characterization of disease subgroups.
    Taïeb D; Jha A; Treglia G; Pacak K
    Endocr Relat Cancer; 2019 Nov; 26(11):R627-R652. PubMed ID: 31561209
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Succinate Mediates Tumorigenic Effects
    Matlac DM; Hadrava Vanova K; Bechmann N; Richter S; Folberth J; Ghayee HK; Ge GB; Abunimer L; Wesley R; Aherrahrou R; Dona M; Martínez-Montes ÁM; Calsina B; Merino MJ; Schwaninger M; Deen PMT; Zhuang Z; Neuzil J; Pacak K; Lehnert H; Fliedner SMJ
    Front Endocrinol (Lausanne); 2021; 12():589451. PubMed ID: 33776908
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential HIF2α Protein Expression in Human Carotid Body and Adrenal Medulla under Physiologic and Tumorigenic Conditions.
    Celada L; Cubiella T; San-Juan-Guardado J; San José Martínez A; Valdés N; Jiménez-Fonseca P; Díaz I; Enguita JM; Astudillo A; Álvarez-González E; Sierra LM; Chiara MD
    Cancers (Basel); 2022 Jun; 14(12):. PubMed ID: 35740651
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Germline mutations and genotype-phenotype correlations in patients with apparently sporadic pheochromocytoma/paraganglioma in Korea.
    Kim JH; Seong MW; Lee KE; Choi HJ; Ku EJ; Bae JH; Park SS; Choi SH; Kim SW; Shin C; Kim SY
    Clin Genet; 2014 Nov; 86(5):482-6. PubMed ID: 24134185
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Somatic HIF2α Mutation-Induced Multiple and Recurrent Pheochromocytoma/Paraganglioma with Polycythemia: Clinical Study with Literature Review.
    Liu Q; Wang Y; Tong D; Liu G; Yuan W; Zhang J; Ye J; Zhang Y; Yuan G; Feng Q; Zhang D; Jiang J
    Endocr Pathol; 2017 Mar; 28(1):75-82. PubMed ID: 28116635
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metabolome-guided genomics to identify pathogenic variants in isocitrate dehydrogenase, fumarate hydratase, and succinate dehydrogenase genes in pheochromocytoma and paraganglioma.
    Richter S; Gieldon L; Pang Y; Peitzsch M; Huynh T; Leton R; Viana B; Ercolino T; Mangelis A; Rapizzi E; Menschikowski M; Aust D; Kroiss M; Beuschlein F; Gudziol V; Timmers HJ; Lenders J; Mannelli M; Cascon A; Pacak K; Robledo M; Eisenhofer G; Klink B
    Genet Med; 2019 Mar; 21(3):705-717. PubMed ID: 30050099
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sino-European Differences in the Genetic Landscape and Clinical Presentation of Pheochromocytoma and Paraganglioma.
    Jiang J; Zhang J; Pang Y; Bechmann N; Li M; Monteagudo M; Calsina B; Gimenez-Roqueplo AP; Nölting S; Beuschlein F; Fassnacht M; Deutschbein T; Timmers HJLM; Åkerström T; Crona J; Quinkler M; Fliedner SMJ; Liu Y; Guo J; Li X; Guo W; Hou Y; Wang C; Zhang L; Xiao Q; Liu L; Gao X; Burnichon N; Robledo M; Eisenhofer G
    J Clin Endocrinol Metab; 2020 Oct; 105(10):. PubMed ID: 32750708
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Master regulator analysis of paragangliomas carrying SDHx, VHL, or MAML3 genetic alterations.
    Smestad JA; Maher LJ
    BMC Cancer; 2019 Jun; 19(1):619. PubMed ID: 31234811
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetic Analysis of Pheochromocytoma and Paraganglioma Complicating Cyanotic Congenital Heart Disease.
    Ogasawara T; Fujii Y; Kakiuchi N; Shiozawa Y; Sakamoto R; Ogawa Y; Ootani K; Ito E; Tanaka T; Watanabe K; Yoshida Y; Kimura N; Shiraishi Y; Chiba K; Tanaka H; Miyano S; Ogawa S
    J Clin Endocrinol Metab; 2022 Aug; 107(9):2545-2555. PubMed ID: 35730597
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metastatic pheochromocytomas and paragangliomas: where are we?
    Prinzi N; Corti F; Torchio M; Niger M; Antista M; Pagani F; Beninato T; Pulice I; Rossi RE; Coppa J; Cascella T; Giacomelli L; Di Bartolomeo M; Milione M; de Braud F; Pusceddu S
    Tumori; 2022 Dec; 108(6):526-540. PubMed ID: 35593402
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recurrent Mutations of Chromatin-Remodeling Genes and Kinase Receptors in Pheochromocytomas and Paragangliomas.
    Toledo RA; Qin Y; Cheng ZM; Gao Q; Iwata S; Silva GM; Prasad ML; Ocal IT; Rao S; Aronin N; Barontini M; Bruder J; Reddick RL; Chen Y; Aguiar RC; Dahia PL
    Clin Cancer Res; 2016 May; 22(9):2301-10. PubMed ID: 26700204
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Congenital Cyanotic Heart Disease and the Association with Pheochromocytomas and Paragangliomas.
    Jones RB; Cohen DL
    Curr Cardiol Rep; 2023 Nov; 25(11):1451-1460. PubMed ID: 37847359
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma.
    Hadoux J; Favier J; Scoazec JY; Leboulleux S; Al Ghuzlan A; Caramella C; Déandreis D; Borget I; Loriot C; Chougnet C; Letouzé E; Young J; Amar L; Bertherat J; Libé R; Dumont F; Deschamps F; Schlumberger M; Gimenez-Roqueplo AP; Baudin E
    Int J Cancer; 2014 Dec; 135(11):2711-20. PubMed ID: 24752622
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genetics of pheochromocytomas and paragangliomas.
    Opocher G; Schiavi F
    Best Pract Res Clin Endocrinol Metab; 2010 Dec; 24(6):943-56. PubMed ID: 21115163
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumoral EPAS1 (HIF2A) mutations explain sporadic pheochromocytoma and paraganglioma in the absence of erythrocytosis.
    Comino-Méndez I; de Cubas AA; Bernal C; Álvarez-Escolá C; Sánchez-Malo C; Ramírez-Tortosa CL; Pedrinaci S; Rapizzi E; Ercolino T; Bernini G; Bacca A; Letón R; Pita G; Alonso MR; Leandro-García LJ; Gómez-Graña A; Inglada-Pérez L; Mancikova V; Rodríguez-Antona C; Mannelli M; Robledo M; Cascón A
    Hum Mol Genet; 2013 Jun; 22(11):2169-76. PubMed ID: 23418310
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of hypoxia and HIF2α in development of the sympathoadrenal cell lineage and chromaffin cell tumors with distinct catecholamine phenotypic features.
    Richter S; Qin N; Pacak K; Eisenhofer G
    Adv Pharmacol; 2013; 68():285-317. PubMed ID: 24054150
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pseudohypoxic pheochromocytomas and paragangliomas dominate in children.
    Redlich A; Pamporaki C; Lessel L; Frühwald MC; Vorwerk P; Kuhlen M
    Pediatr Blood Cancer; 2021 Jul; 68(7):e28981. PubMed ID: 33682326
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetic and epigenetic differences of benign and malignant pheochromocytomas and paragangliomas (PPGLs).
    Khatami F; Mohammadamoli M; Tavangar SM
    Endocr Regul; 2018 Jan; 52(1):41-54. PubMed ID: 29453919
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hypoxia potentiates the cytotoxic effect of piperlongumine in pheochromocytoma models.
    Bullova P; Cougnoux A; Abunimer L; Kopacek J; Pastorekova S; Pacak K
    Oncotarget; 2016 Jun; 7(26):40531-40545. PubMed ID: 27244895
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.